At an airport hotel outside of Madrid, researchers hunkered down for the better part of a week to trade news about clinical trials for Alzheimer’s disease. The field is watching the rollout for lecanemab and donanemab with bated breath, tweaking administration, debating appropriate use, and hoping for no more deaths. Meanwhile, brain shuttle versions are on the horizon, led by trontinemab. Tau as a target is beginning to yield to mid-region antibodies, though OGA inhibition appears too toxic in its current form. While gene-based therapies are showing promise in small trials, the big push is to test anti-amyloid antibodies in large prevention trials, and to whip blood-based biomarkers into shape to become in vitro diagnostics (IVDs) suitable for routine use at a doctor’s office near you. Read all about it in the stories below.
